UK and EU cosmetics regulations require every ingredient to be listed on the label using its standardised INCI name, in descending order of concentration. This means the full ingredient list on the back of the packaging always contains the answer, provided you know which INCI name corresponds to the marketed ingredient. Copper Tripeptide-1 is GHK-Cu. Copper Tripeptide-3 is AHK-Cu. Sodium Hyaluronate is what brands typically mean when they say "hyaluronic acid." The EU Commission's CosIng database at ec.europa.eu/growth/tools-databases/cosing lists INCI names for any registered cosmetic ingredient.

A product that does not list its ingredients in INCI format, or that describes actives only by trade names without any verifiable INCI equivalent, is not compliant with UK cosmetics regulations. That non-compliance is itself a signal. More commonly, products are technically compliant but rely on buyers not knowing how to read the list. The article on why INCI order tells you more than the ingredients list covers how to read that information in practice.

Concentration disclosure is voluntary in the UK. Most brands do not disclose it. When a brand does not state the concentration directly, the INCI list provides the best available indirect signal: INCI ingredients are listed in descending order of weight, so the position of the active relative to known reference ingredients tells you something about its approximate concentration bracket. An active appearing before the preservative system is likely at or above 1%. One appearing after the sodium hyaluronate is probably below 0.2%.

The research literature on actives like copper peptides typically uses concentrations in a range that can be roughly inferred from this kind of INCI reading. When a brand markets a "high-concentration" serum and the active appears eighth in the ingredient list, behind several solvents and thickeners, there is a meaningful discrepancy between the claim and what the label suggests. The article on copper peptide concentration and what most labels don't tell you covers this evaluation process in more detail.

A useful hierarchy to apply when reading product claims:

Very few topical hair loss actives have strong human clinical trial evidence. Minoxidil and finasteride are the main exceptions. Most copper peptide research, most peptide research generally, and all research on newer compounds like PTD-DBM rests on in vitro and animal data of varying quality. That does not mean those products are ineffective; it means the question of human efficacy is genuinely open, and any brand that speaks as though it is settled is overstating what the evidence supports. A brand that accurately describes the level of its evidence, using language like "research in mouse models suggests" or "in vitro studies indicate," is demonstrating something worth valuing even before you evaluate the product itself.

The most common forms of hair loss have distinct underlying mechanisms. Androgenetic alopecia (AGA) is driven primarily by DHT acting on androgen-sensitive follicles, producing progressive miniaturisation. Telogen effluvium is a diffuse shedding response to systemic stress, nutritional deficiency, hormonal change, or illness; the follicles themselves are not damaged, and the condition is often self-resolving once the trigger is removed. Female pattern hair loss (FPHL) shares some mechanisms with AGA but often without the same androgen sensitivity, making DHT-targeted treatments less predictably effective. Alopecia areata is autoimmune.

A topical serum that supports the follicular environment is a reasonable adjunct for AGA. It is not a treatment for autoimmune alopecia areata and is unlikely to address the underlying trigger in telogen effluvium. Knowing which condition you have (ideally confirmed by a dermatologist) is prerequisite to evaluating whether a specific product is appropriate. The article on the hair growth cycle and the article on DHT and the follicle provide background for understanding how AGA specifically develops.

This question also applies within AGA: different products act at different layers of the same disease process. DHT suppression (finasteride, dutasteride) addresses the androgen signal upstream. Minoxidil addresses vascular support and anagen prolongation. Copper peptides address the follicular microenvironment. A Wnt pathway compound like PTD-DBM addresses intracellular signalling suppression. These are different layers, not competing alternatives. Understanding which layers your current protocol covers and which it does not is the most useful framing for evaluating whether any new product is genuinely additive.

The most practically significant carrier ingredient to check for is DMSO (dimethyl sulfoxide). DMSO is a pharmaceutical solvent sometimes used to drive poorly soluble actives through the skin. Its key property, which makes it both useful and problematic, is that it is non-selective: it enhances the penetration of whatever else is present on the skin at the time, not just the intended active. For someone using a serum alongside minoxidil, topical finasteride, copper peptides, or other scalp actives, DMSO could drive those co-applied compounds through the barrier at rates they were not formulated to deliver. For anyone running a protocol with multiple topicals, this variable is worth understanding before adding a DMSO-containing product.

Glycols (propylene glycol and butylene glycol are the most common) are worth checking for if you have skin sensitivities or are using microneedling in your protocol. Both are effective solvents and humectants, but some users find them irritating, and their penetration-enhancing properties under microneedling conditions mean a serum formulated with them behaves differently when applied post-needling than it would on intact skin. A glycol-free formula removes that variable. The article on microneedling and topical actives covers this in more detail.

A simpler carrier is generally easier to evaluate than a complex one. A formula with six or seven ingredients, each with a known purpose, is more legible than one with twenty-five including multiple unnamed emulsifiers and fragrance compounds. Fragrance in a scalp product adds potential irritation risk without therapeutic benefit and is worth noting.

AmpleLab's products are designed to answer all five questions directly. Every product in the range states the active concentration on the label, uses standardised INCI names throughout, discloses the full ingredient list with no proprietary blends, describes its research basis with explicit caveats about evidence type, and formulates in glycol-free aqueous carriers without DMSO. That transparency is the brand's core positioning, not a feature of specific products.

Current products address different layers of the hair loss mechanism: the 1% AHK-Cu Hair and Scalp Serum and 1% GHK-Cu Face and Skin Serum are oriented toward the follicular microenvironment; the 2% 2dDR Hair Serum addresses the vascular environment. Each targets a different layer, and none claims to address what it does not. The hair loss protocol framework covers how to think about combining different approaches systematically.

This article is provided for educational purposes. AmpleLab products are cosmetic formulations. For diagnosis of hair loss conditions or medical advice on treatment, consult a qualified healthcare professional.

AmpleLab.